Monoclonal Antibody Treatment
COVID-19 Treatment

Monoclonal antibodies are lab-created proteins that mimic the ones our bodies produce to fight viruses. The antibodies defend the body by blocking Covid-19 viruses from attaching to human cells.

Bebtelovimab, pronounced: beb-te-LOV-i-mab

Bebtelovimab is a neutralizing antibody drug. When there’s a virus in your body, like COVID-19, your immune system makes antibodies to fight it off. But it takes time for your body to make antibodies for a new virus — and in the meantime, you could get very sick. Bebtelovimab contains man made antibodies to help fight the virus. They do not have any COVID-19 virus in them.

Bebtelovimab is NOT authorized for use in people who:

• are hospitalized due to COVID-19
• require oxygen therapy and/or respiratory support due to COVID-19
• require an increase in baseline oxygen flow rate and/or respiratory support due to COVID-19 and are on chronic oxygen therapy and/or respiratory support due to underlying non-COVID-19 related comorbidity.

Bebtelovimab will be given as an injection through a vein (intravenously or IV) over at least 30 seconds. You will be observed for at least 1 hour after you receive bebtelovimab.

In order to ensure the safety and comfort of our patients, we offer this treatment in a house call setting.

• Allergic reactions. Allergic reactions can happen during and after injection with bebtelovimab. Tell your healthcare provider right away if you or your child develop any of the following signs and symptoms of allergic reaction: fever, difficulty breathing, low oxygen level in your blood, chills, tiredness, fast or slow heart rate, chest discomfort pain, weakness, confusion, nausea, headache, shortness of breath, low or high blood pressure, wheezing, swelling of your lips, face, or throat, rash including hives, itching, muscle aches, dizziness, feeling faint, and sweating. These reactions may be severe or life threatening. 
• The side effects of receiving any medicine by vein may include brief pain, bleeding, bruising of the skin, soreness, swelling, and possible infection at the injection site.

Bebtelovimab has not been approved, but has been authorized for emergency use by the FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death and for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate.

Yes. Eligibility for Monoclonal Antibody IV Treatment currently requires that you have recently tested positive for Covid-19.